The active drug in Zepbound® and Mounjaro®

What tirzepatide is, how it is dosed, and how it compares with semaglutide

Two Eli Lilly brands contain tirzepatide, and pharmacies compound it too. An AM Rx provider reads your health history online and prescribes it only if it is appropriate for you.

  • A single weekly injection aimed at two receptors, GIP and GLP-1
  • With plan coverage, a Zepbound or Mounjaro copay may be as low as $25 a month*
  • Compounded tirzepatide: $329 monthly, or $216/mo and up with a 3-month supply†
  • Available in all 50 states and Washington, DC, to eligible adults
Zepbound, Ozempic, Mounjaro and Wegovy injection pens side by side on a green background
Brand tirzepatide · $25/mo copay possible if covered*
Map of the United States reading “Compounded by Licensed Pharmacies in the USA”
Compounded tirzepatide · $216/mo and up†
Phone screen asking “What is your desired weight?” beside a medication card
Your intake goes to a licensed provider
$25/moLowest brand copay, if your plan pays*
$216/moCompounded, lowest price, 3-month supply†
$39Membership, month one
Tirzepatide in one paragraph

It is a weekly injection that switches on two hormone receptors, GIP and GLP-1. The FDA first approved it in 2022 under the name Mounjaro, to treat type 2 diabetes.1 In November 2023 the same drug was approved as Zepbound for chronic weight management.2 Both come from Eli Lilly.

Zepbound, Mounjaro or compounded: which is which?
  • Zepbound holds FDA approval for chronic weight management, and also for adults who have obesity together with moderate to severe obstructive sleep apnea. More on Zepbound.
  • Mounjaro holds FDA approval for type 2 diabetes. Weight loss is not on its label, which makes that use off-label. More on Mounjaro.
  • Compounded tirzepatide is mixed for one patient by a pharmacy. It is neither FDA-approved nor a generic, and its safety, effectiveness and quality get no FDA review.3,4 More below.
How is tirzepatide dosed?

Weekly, opening with four weeks at 2.5 mg and then 5 mg. Further increases are 2.5 mg each, at least four weeks apart, to a 15 mg ceiling.5 Dosage table.

*Your plan decides coverage; approval is never guaranteed. A $25 fill generally takes a commercial plan that pays for the brand, together with Lilly’s savings card, which excludes people on Medicare, Medicaid, VA, TRICARE or any other government plan. †With a 3-month supply; $329 billed monthly. Not FDA-approved. Membership is extra ($39, then $135 a month).

Safety summary: The label for tirzepatide has a boxed warning on thyroid C-cell tumors. It must not be used by anyone who has had medullary thyroid carcinoma (MTC), whose relative has had it, or who has MEN 2 (Multiple Endocrine Neoplasia syndrome type 2). Full details.

Tirzepatide’s main obesity trial: 15% to 21% of body weight lost, rising with the dose

SURMOUNT-1 enrolled 2,539 adults. All had obesity, or were overweight with a related health condition, and none had diabetes. Average weight loss after 72 weeks was 15.0% at the 5 mg dose, 19.5% at 10 mg and 20.9% at 15 mg. With placebo it was 3.1%.6

Loss at the 15 mg
average (20.9%)
52lbs

Same sum for the 5 mg and 10 mg averages: 38 and 49 lbs

The slider multiplies your weight by a trial average and cannot forecast your result. At 15 mg roughly 57% of people shed a fifth of their weight or more, and roughly 9% shed under 5%.5 Participants were also coached on diet and exercise. The drug tested was Lilly’s, not a compounded one.

With type 2 diabetes

SURMOUNT-2, 72 weeks: 12.8% (10 mg) and 14.7% (15 mg), with 3.2% for placebo.5

Against semaglutide

SURMOUNT-5, 72 weeks: 20.2% with tirzepatide, 13.7% with semaglutide.7 Full comparison.

After stopping

SURMOUNT-4: people switched to placebo at week 36 regained 14.0% within a year. People kept on the drug lost a further 5.5%.5

All four trials were paid for by Eli Lilly and used its own tirzepatide. Results differ between individuals.

One drug behind two brand names

Only two FDA-approved products contain tirzepatide, Zepbound and Mounjaro. Eli Lilly makes both in six identical weekly strengths.1,5 They differ in the conditions each is approved for, which is what insurers go by.

FeatureZepboundWeight and sleep apneaMounjaroType 2 diabetes
FDA-approved usesReducing excess body weight, and maintaining the reduction, in adults who have obesity or who are overweight with a weight-related condition. Treating obstructive sleep apnea that is moderate to severe in adults who also have obesity.Controlling blood sugar in people aged 10 and over who have type 2 diabetes. Reducing major cardiovascular events (heart attack, stroke, cardiovascular death) in high-risk adults who have type 2 diabetes.
Is weight loss on the label?YesNo, so prescribing it for weight alone is off-label
Weekly strengthsSix: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Forms LillyDirect sellsKwikPen, single-dose vials, single-dose pens8Single-dose pens

There is a third route, compounded tirzepatide. It lacks FDA approval and is covered further down.

How tirzepatide works

Tirzepatide is a single molecule that acts as an agonist at both the GIP receptor and the GLP-1 receptor. Semaglutide targets only the second.5,9 Zepbound’s label says GLP-1 helps regulate appetite and calorie intake, and that studies outside humans suggest GIP may contribute too.

People taking tirzepatide eat less. Their stomachs also empty more slowly, most of all after the first dose. The drug raises insulin release at times of high blood sugar and reduces glucagon. Its half-life is roughly five days, which fits a weekly schedule.5

In short

  • Class: dual GIP and GLP-1 receptor agonist
  • Generic or pill: neither exists. FDA’s records hold just those two tirzepatide products.10
  • Paired with: eating fewer calories and moving more

From intake to first dose with AM Rx

A licensed provider judges whether tirzepatide suits you and in which form, all online.

Five steps, no waiting room
1. Join, then answer the intake

Membership costs $39 for month one. In the intake you give your weight, medical history, current medicines and goals.

Phone screen asking “What is your desired weight?” beside a medication card
2. A provider goes through it

New intakes reach a U.S.-licensed, board-certified physician or nurse practitioner, who reviews them in 1 to 2 business days and writes back by secure message. You can start without a live appointment.

Hands holding a phone that shows a message thread with a provider
3. Brand prescribed? We handle the paperwork

For Zepbound or Mounjaro, the prior authorization is filed by our insurance coordination team. Plans mostly answer within 2 to 14 business days, and the team can file up to three requests after a denial. If the plan pays, your copay may be as low as $25 per month at the pharmacy you pick. An authorization stays active only while your membership does.

A man in a knit hat holding a phone and a mug
4. Compounded prescribed? It comes by mail

Processing at a partner pharmacy usually takes 2 to 7 business days, followed by 2-day delivery, so most members receive it 2 to 9 business days after the prescription. Supplies come with it. A 3-month supply is usually three vials in a single shipment. This product is not FDA-approved.

A woman in workout clothes laughing against a red wall
5. Dose changes stay with the same team

Secure messages to your provider and care team are unlimited. You also get a dedicated weight loss coach and, on request, a monthly video or phone visit, all inside the AM Rx app and portal.

A man at home smiling at his laptop
A woman laughing while looking at her phone

What an AM Rx membership includes

  • A licensed provider’s review, plus a prescription if one is appropriate
  • Prior authorization paperwork for Zepbound or Mounjaro
  • Secure messaging without limits
  • Monthly video or phone visits for members who ask
  • Your own weight loss coach
  • App and online portal
$39Month one
$135/moFrom month two

The price of medication is extra. You may cancel in the portal whenever you like, and we take HSA and FSA cards.

Get Started

Tirzepatide side effects at each dose, with placebo for comparison

Nausea leads the list. In the weight trials behind Zepbound, between 25% and 29% of adults on tirzepatide reported it, and 8% of those on placebo did. Stomach complaints clustered in the weeks when doses were being raised.5

Side effectPlacebo5 mg10 mg15 mg
Nausea8%25%29%28%
Diarrhea8%19%21%23%
Constipation5%17%14%11%
Vomiting2%8%11%13%
Stomach pain5%9%9%10%
Indigestion4%9%9%10%
Injection site reaction2%6%8%8%
Hair loss1%5%4%5%

Pooled figures for adults in SURMOUNT-1 and SURMOUNT-2, both placebo-controlled trials of Zepbound.5 Neither included compounded tirzepatide.

What can help

  • Smaller meals, eaten more often.11
  • Less fatty and high-fiber food during the first few days if nausea sets in.11
  • Steady fluids whenever you vomit or have diarrhea, because dehydration can injure the kidneys.5
  • A message to your provider if a dose feels like too much.

Seek medical help at once if you have

  • Severe stomach-area pain that does not ease, whether or not you are vomiting
  • Pain high in the stomach area together with fever, yellowing skin or eyes, or pale, clay-colored stools
  • Swelling in your face, lips, throat or tongue, breathing trouble, or a severe rash
  • Sudden loss of sight in one eye
  • A neck lump, a hoarse voice that lingers, or difficulty swallowing (see the boxed warning)5,12

How long the side effects go on

The labels give a pattern, not a number of days. Nausea, vomiting and diarrhea were mostly reported while doses were being raised, and less often afterward. Between 4.8% and 6.7% of adults on Zepbound quit treatment because of side effects; for placebo the figure was 3.4%.5 Mounjaro’s diabetes trials, in a different population, recorded nausea in 12% to 18%.1

A new eye warning from the FDA

The FDA announced on November 9, 2026 that every drug in this class, Zepbound and Mounjaro among them, must add label language about NAION, an uncommon optic nerve condition that can take the sight from one eye suddenly and without pain. The FDA calls the added risk potential, and Lilly’s labels had not changed by November 19, 2026.12 The GLP-1 side effects guide goes further.

Tirzepatide dosage: 2.5 mg to begin, rising in 2.5 mg steps to a 15 mg weekly maximum

You inject tirzepatide once every week. A dose has to be used for four weeks or longer before the next 2.5 mg increase, which puts 15 mg no closer than 20 weeks after the first injection.5

When (earliest)Dose each weekPurpose
Weeks 1 to 42.5 mgWhere everyone begins. Zepbound’s label does not allow it long term.
Weeks 5 to 85 mgThe smallest maintenance dose for weight management.
Weeks 9 to 127.5 mgA step between two maintenance doses.
Weeks 13 to 1610 mgMaintenance for weight management, and one of two sleep apnea doses.
Weeks 17 to 2012.5 mgThe last step before the top dose.
Week 21 and later15 mgThe top maintenance dose. Nothing higher is approved.

No faster schedule is permitted by Zepbound’s label.5 A provider may hold a dose for longer or settle on a lower one. Body weight plays no part in choosing the dose.

By product

  • Zepbound for weight: 5, 10 or 15 mg weekly.
  • Zepbound for sleep apnea: 10 or 15 mg weekly.
  • Mounjaro: raised above 2.5 mg only when blood sugar calls for it; 15 mg is the adult limit.1
  • Compounded: whatever your prescription label states.

Missed dose or new day

  • Within 4 days (96 hours): inject as soon as possible.
  • Beyond 4 days: leave that dose out and inject on your regular day.
  • Switching days is fine when 3 days (72 hours) or more separate two doses.5

Giving the injection

  • Whatever hour suits you, with a meal or without.
  • Thigh or stomach area if you inject yourself; back of the upper arm only if another person does it.
  • Pick a fresh spot every week.5

Why vial doses are given in units

Brand-name pens come pre-measured. With a compounded vial you pull each dose into an insulin syringe marked in units of volume, 100 to the mL.13 AM Rx’s compounded vial holds 10 mg in each mL, so 10 units equal 1 mg: 25 units for 2.5 mg, 50 units for 5 mg. Other concentrations give other numbers. Every dose is charted in our tirzepatide dosing in units guide.

Some adverse event reports sent to the FDA may be linked to compounded semaglutide or tirzepatide prescribed outside the approved label: bigger, more frequent or faster-rising doses.3 At AM Rx, extra fees can apply to a dose above the standard schedule.

Semaglutide versus tirzepatide: one direct trial, and what each offers that the other lacks

Only one large trial has set the two drugs against each other for weight loss, and tirzepatide came out ahead: 20.2% of body weight lost, compared with 13.7%, across 72 weeks.7

FeatureTirzepatideSemaglutide
ReceptorsGIP plus GLP-1GLP-1 only
Weight-loss brandZepbound (adults)Wegovy® (adults; the injection from age 12)9
Other approvalsZepbound for sleep apnea with obesity. Mounjaro for type 2 diabetes.Wegovy for cutting heart attack and stroke risk in adults who have heart disease and excess weight, and for MASH, a liver disease. Ozempic® for type 2 diabetes only, so weight loss is off-label.9,14
Head-to-head, 72 weeks20.2% lighter13.7% lighter
Weekly weight-loss doses2.5 mg through 15 mg0.25 mg through 2.4 mg, then 7.2 mg at most
Tablet availableNoYes: Wegovy, taken daily
Nausea in its own trials25% to 29%44%
AM Rx compounded price$329 monthly; $216/mo and up for three months at once$199 monthly; $106/mo and up for three months at once

Nausea figures are from separate trials and cannot be compared directly.5,9 No compounded medication is FDA-approved, and none was part of these trials. See also our semaglutide page.

The head-to-head trial: SURMOUNT-5

The trial had 751 participants, all adults with obesity and none with type 2 diabetes. Doses were pushed to the highest each person tolerated: tirzepatide 10 mg or 15 mg, semaglutide 1.7 mg or 2.4 mg. Nobody was blinded to their drug.7

  • Weight after 72 weeks: 20.2% lower versus 13.7% lower. From 220 pounds, the averages work out near 44 and 30 pounds.
  • Waist: 18.4 cm off versus 13.0 cm off.
  • Caveats: Eli Lilly paid for it, and the 7.2 mg strength of Wegovy was not part of it.

In type 2 diabetes: SURPASS-2

SURPASS-2 ran for 40 weeks in 1,879 adults who had type 2 diabetes. Tirzepatide (5 mg to 15 mg) took off 7.6 kg to 11.2 kg. Semaglutide took off 5.7 kg at 1 mg, half the highest Ozempic dose.1,14 More in Mounjaro vs Ozempic.

Tirzepatide may suit you better if

  • Your plan pays for Zepbound or Mounjaro.
  • You have obesity with obstructive sleep apnea (see Zepbound for sleep apnea).
  • Losing as much weight as possible is the main goal.

Semaglutide may suit you better if

  • Wegovy or Ozempic is what your plan pays for.
  • You have heart disease but not diabetes. Wegovy has a heart indication; Zepbound has none.
  • A tablet appeals more than an injection.
Prices as of November 2026

Tirzepatide cost: insured, uninsured, and through AM Rx

One month of tirzepatide can run from $25 to over $1,000. Three things set the figure: the product, whether a plan pays, and which Lilly program fits you.

Your situationLikely priceNotes
A commercial plan pays for the brandA fill for $25 at the lowestNeeds Lilly’s savings card, worth up to $100 off a month of Zepbound and up to $150 off a month of Mounjaro.15
A commercial plan refuses the brand$299 to $499 monthlyCard prices: $299 to $449 for a Zepbound KwikPen, $499 for single-dose pens of either brand.15
Uninsured, buying from LillyZepbound: 2.5 mg $299, 5 mg $399, 7.5 mg and up $449. Mounjaro: $499 or moreZepbound as a KwikPen or vials. The $449 price holds only when you refill inside 45 days.8
List price$499 to $1,086.37 per Zepbound fill; $1,112.16 per Mounjaro fillLilly’s published price before insurance or discounts.16
AM Rx compounded tirzepatide$329 for a single month, or $216 and up per month when you order threeShipping is in the price. Not FDA-approved.
Medicare GLP-1 Bridge$50 monthly for a Zepbound KwikPenFor qualifying Part D members, July 1, 2026 to December 31, 2027. Other Zepbound forms and Mounjaro are excluded.17

Lilly sets brand prices and card rules. Its savings cards all end on December 31, 2026, with nothing posted for 2027 as of November 19, 2026. AM Rx medication prices leave out membership.

Tirzepatide cost with insurance

If a commercial plan pays for your brand, a fill can come down to $25. Diabetes use has generally been covered, yet KFF’s 2026 survey found just 18% of employers with at least 200 workers covering these drugs for weight loss.18 Our team files the prior authorization, though approval is never certain. Start with the GLP-1 insurance checker.

What tirzepatide costs if you are uninsured

Paying on your own, expect $299 to $699 monthly for the FDA-approved product at Lilly’s self-pay rates. The $449 Zepbound price depends on refilling inside 45 days. Past that window, 7.5 mg costs $499 and stronger doses cost $699.8 None of this spending counts toward a deductible.15

Manufacturer savings cards

Each Lilly savings card is tied to one brand, and using one takes commercial insurance plus a Zepbound or Mounjaro prescription. The cards are closed to anyone on Medicare, Medicaid, VA, TRICARE or other government-funded coverage. Mounjaro’s card works only for its approved use, type 2 diabetes.15 Terms in full: Zepbound, Mounjaro.

Buying direct from Lilly

Eli Lilly runs LillyDirect, a pharmacy channel that fills prescriptions but does not write them. It is the sole source of Zepbound single-dose vials, which are self-pay only. A self-pay card extends the same KwikPen prices to retail pharmacies. For Mounjaro, LillyDirect carries single-dose pens.8,15

What you pay through AM Rx

  • Membership: $39 the first month and $135 each month after.
  • Zepbound or Mounjaro: paid to your pharmacy. A covered copay may be as low as $25 monthly.
  • Compounded tirzepatide: $329 if billed month by month, or $216 and up per month with a 3-month supply.
  • Bundle: membership and compounded tirzepatide in one charge, $349 in the first month and $449 monthly afterward.

We accept HSA and FSA cards. Members found not clinically eligible get a refund.

Offers to be wary of

Among the FDA’s red flags for online sellers: implausibly low prices, no prescription from a licensed doctor, and a seller saying its compounded drug matches an FDA-approved one.3 To weigh local clinics against online care, see tirzepatide near me.

Compounded tirzepatide and the FDA’s position on it

A pharmacy mixes compounded tirzepatide to fill a single patient’s prescription. The FDA has not approved it, and that means no FDA review of its safety, effectiveness or quality before a patient receives it.3

Not a generic, and not Zepbound

Generics are FDA-approved copies of brand drugs; compounded drugs carry no FDA approval.4 The FDA’s records contain two approved tirzepatide products and no others: Mounjaro and Zepbound.10 Every trial result on this page comes from them. Compounded tirzepatide took no part in those trials, and we make no claim that it is equivalent or equally effective.

The FDA’s position

  • Who it is for. In the FDA’s view, a compounded drug belongs only with a patient whose medical need an FDA-approved drug cannot meet.3
  • The shortage has ended. In 2024 the FDA ruled that tirzepatide was no longer in shortage. The grace periods it allowed compounders ran out in March 2025.19
  • April 1, 2026. Tirzepatide, the FDA noted, appears neither on the drug shortage list nor on the bulk-substance list that governs outsourcing facilities. A state-licensed pharmacy may not, regularly or in inordinate amounts, compound a drug that is essentially a copy of one already commercially available. The exception is a prescriber who determines and documents a change producing a significant difference for an identified individual patient. Enforcement is not planned against a compounder filling four or fewer such prescriptions in a calendar month.19
  • Added ingredients. That statement also covers combinations. The FDA may regard a compounded product pairing semaglutide with a second active ingredient, for example vitamin B12 (cyanocobalamin), as essentially a copy if it is given by the same route as the commercial drugs and each amount falls within 10% of the commercial strength. The rule applies to compounded drugs in general; the example does not mention tirzepatide.19
  • Unknowns. A separate FDA alert about compounded semaglutide states that combining it with other ingredients, vitamin B12 included, has not been established as safe or effective.13
  • Adverse events. Up to May 31, 2026, more than 730 reports tied to compounded tirzepatide had reached the FDA, which considers under-reporting likely.3

AM Rx’s compounded tirzepatide

  • Vial: 2 mL, 10 mg per mL, 20 mg in total
  • Second ingredient: cyanocobalamin (vitamin B12), 500 mcg in each mL
  • On a U-100 insulin syringe: 10 units is 1 mg
  • FDA approval: none
  • Prescriber: a licensed provider, and only if it is appropriate for you
  • Source: a partner pharmacy, which ships it with supplies

Handling a vial

  • FDA advice: discard a multi-dose vial 28 days after its first use, whatever is left inside.
  • Each dose needs a new, sterile syringe and needle.
  • An injectable GLP-1 that turns up warm should not be used.3
FeatureZepbound or MounjaroCompounded tirzepatide
FDA-approvedYesNo
MakerEli LillyA partner pharmacy, one prescription at a time
Used in the trials cited hereYesNo
Price of medicationA copay that may be as low as $25 monthly, given plan coverage$329 monthly, or $216 and up per month for a three-month supply
Get Started
Five Wegovy pens, one of each dose strength

Tirzepatide is not the only choice

AM Rx providers prescribe semaglutide as well, under the same membership.

AM Rx members

AM Rx members, in their own words

One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
Michelle, 33 | Lost 48 pounds
I started semaglutide at the recommendation of my AM Rx provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Michael, 37 | Lost 29 pounds
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and AM Rx was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Susanne, 60 | Lost 33 pounds
Since I started AM Rx, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
Rachel | AM Rx Member
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
John | AM Rx Member
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Sara | AM Rx Member

Individual results may vary. These reviews describe the experience of individual AM Rx members and do not promise any result. Medication is prescribed only if a licensed provider considers it appropriate.

A man at home smiling at his laptop
Your care team

Whether tirzepatide is prescribed is a provider’s call

Before anything is prescribed, your intake is read by a physician or nurse practitioner who holds a license in your state. That person picks Zepbound, Mounjaro or compounded tirzepatide only if one of them suits you, and says so plainly if none does.

50 states and DCU.S.-licensed physicians and nurse practitioners, wherever you live
No appointment to bookA provider reads your intake online and replies by secure message
Open every dayPhone support Monday to Friday 9am to 8pm ET, weekends 12pm to 8pm ET

The AM Rx care team checks the medical content of this page against FDA prescribing information and published clinical trials. It is general health education and does not replace advice from your own provider.

Tirzepatide questions, answered

How many milligrams of tirzepatide do you take each week?

Anywhere from 2.5 mg to 15 mg, in a single weekly injection. Zepbound begins with four weeks at 2.5 mg, moves up to 5 mg, and may then climb by 2.5 mg every four weeks or longer. See the dosage table.

Does tirzepatide work better than semaglutide for weight loss?

In the single large trial comparing them, yes. SURMOUNT-5 lasted 72 weeks and enrolled adults with obesity. Average weight loss reached 20.2% in the tirzepatide group and 13.7% in the semaglutide group. Tirzepatide’s maker funded it, and individuals respond differently. More under semaglutide versus tirzepatide.

Are compounded tirzepatide and Zepbound the same thing?

No. Zepbound is Eli Lilly’s FDA-approved product. Compounded tirzepatide comes from a pharmacy that makes it for a single prescription. It has no FDA approval and no FDA review of its safety, effectiveness or quality. It does not count as a generic either. Trial results quoted here are Lilly’s.

What does AM Rx’s compounded tirzepatide vial contain?

A 2 mL vial contains 20 mg of tirzepatide (10 mg per mL) plus cyanocobalamin, a form of vitamin B12, at 500 mcg per mL. It is not FDA-approved. On April 1, 2026 the FDA explained that it may regard a compounded product pairing semaglutide with a second active ingredient, vitamin B12 for example, as essentially a copy of marketed drugs. Details above.

How many units on a syringe is 2.5 mg of tirzepatide?

That depends on how concentrated the vial is. Units measure volume, with 100 to the mL. AM Rx’s compounded vial is 10 mg per mL, which makes 2.5 mg 25 units and 5 mg 50 units. Go by your own label and the units guide.

How much is tirzepatide a month without insurance?

Roughly $216 to $699 in November 2026. Lilly sells Zepbound to self-payers at $299 (2.5 mg), $399 (5 mg) and $449 (higher doses, refilled inside 45 days). Mounjaro begins at $499. AM Rx’s compounded tirzepatide, not an FDA-approved product, is $329 a month, or $216 and up on a three-month supply, plus membership.

Will insurance pay for tirzepatide for weight loss?

Only when the plan includes weight-loss medication, which most employer plans leave out: 18% of larger employers covered it in KFF’s 2026 survey. For weight, plans look at Zepbound, since Mounjaro’s approval is for type 2 diabetes. AM Rx can file a prior authorization up to three times.

Important safety information

What follows is drawn from the FDA-approved labels of Zepbound and Mounjaro.1,5 No FDA-approved label exists for compounded tirzepatide. Its active ingredient is the same, so every warning here should be read as applying to it.

Boxed warning: thyroid C-cell tumors

In rats, tirzepatide causes thyroid C-cell tumors. Nobody knows whether it does so in humans, and that includes medullary thyroid carcinoma (MTC), a type of thyroid cancer. Tirzepatide is not for you if MTC has ever been diagnosed in you or a relative, or if you have MEN 2 (Multiple Endocrine Neoplasia syndrome type 2). Let your provider know about a neck lump or swelling, a hoarse voice that lingers, difficulty swallowing, or breathlessness.

Do not take tirzepatide if you

  • Have had MTC, have a relative who has, or have MEN 2.
  • Have ever had a serious allergic reaction to it, or to anything else the product contains.

Before starting, let your provider know if you

  • Have, or once had, a problem with your pancreas.
  • Have a severe stomach condition such as gastroparesis.
  • Have had diabetic retinopathy.
  • Use insulin, a sulfonylurea or any other diabetes medicine.
  • Have an operation, or a procedure under anesthesia or deep sedation, coming up.
  • Are pregnant, hope to become pregnant, or are breastfeeding. Zepbound is to be stopped once a pregnancy is recognized.
  • Take a birth control pill, warfarin, or other medicine by mouth.
  • Already use a tirzepatide or GLP-1 product.5

Sources

  1. Mounjaro Prescribing Information. Eli Lilly. Revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
  2. FDA. FDA Approves New Medication for Chronic Weight Management. November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  3. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  4. FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. Zepbound Prescribing Information and Medication Guide. Eli Lilly. Revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf and https://pi.lilly.com/us/zepbound-us-mg.pdf
  6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  7. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
  8. Eli Lilly. LillyDirect: Zepbound and Mounjaro. https://www.lilly.com/lillydirect/zepbound and https://www.lilly.com/lillydirect/medicines/mounjaro
  9. Wegovy Prescribing Information. Novo Nordisk. Revised June 2026. https://www.novo-pi.com/wegovy.pdf
  10. FDA. Drugs@FDA records for tirzepatide. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22TIRZEPATIDE%22&limit=50
  11. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. Obesity. 2025;33(8):1475-1503. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304835/
  12. FDA. Drug Safety Communication on GLP-1 receptor agonists and NAION. November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  13. FDA. Alert on dosing errors with compounded injectable semaglutide. July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  14. Ozempic Prescribing Information. Novo Nordisk. Revised May 2026. https://www.novo-pi.com/ozempic.pdf
  15. Eli Lilly. Savings terms for Zepbound and Mounjaro. https://zepbound.lilly.com/savings and https://mounjaro.lilly.com/savings-coverage
  16. Eli Lilly. List prices: Zepbound and Mounjaro. https://pricinginfo.lilly.com/zepbound and https://pricinginfo.lilly.com/mounjaro
  17. Medicare.gov. Weight loss drugs. https://www.medicare.gov/coverage/weight-loss-drugs
  18. KFF. 2026 Employer Health Benefits Survey. https://www.kff.org/health-costs/2026-employer-health-benefits-survey/
  19. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entry of April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

Reviewed by the AM Rx care team. Web sources accessed November 19, 2026.

See whether tirzepatide makes sense for you

Complete the online intake and a licensed provider will go through it. Month one of membership costs $39.

Get Started